What Eli Lilly and Company calls proof-of-concept data for LY-CoV555, its neutralizing antibody candidate for the novel coronavirus, is meeting pushback from analysts, but a top Lilly exec told Scrip that the particulars and limitations of the dataset are less important than the demonstration that an antibody therapy can provide benefit to COVID-19 patients.
The Indianapolis pharma reported on 16 September that an interim analysis of the Phase II BLAZE-1 study showed that one...






